Incorporated in 1941, Chong Kun Dang Pharmaceutical Corp. ("CKD Pharm") is one of Korea's largest manufacturers of antibiotics. CKD Pharm manufactures and markets over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis.  Noteworthy products include Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent). CKD Pharm is also focusing its research capabilities on developing new drugs, value-added formulations of new generic drugs and technologies as well as enhancing its expertise in fermentation and organic synthesis.